Q: Hi 5i team,
RAD is up significantly over the past years. Still highly leveraged, the interest rate environment plays in their favor. Restructuring charges seem to be in the past. Their strategy: remodeling stores, wellness rewards program, better buying cost management, etc. seem to be driving same store sales and earnings growth despite the generic drug impact. Demographic evolution of the US population should help. I expect RAD to make its entrance in the S&P500 in a not too distant horizon (2 years? which is well inside my investment horizon). It might look a little expensive, and be a little volatile.
I would like to have your thoughts on the company (including on management). Besides reimbursement program, what are the main threats? Is this a good way to get a first direct exposure to the US economy in a portfolio?
Thank you for your help, Eric
RAD is up significantly over the past years. Still highly leveraged, the interest rate environment plays in their favor. Restructuring charges seem to be in the past. Their strategy: remodeling stores, wellness rewards program, better buying cost management, etc. seem to be driving same store sales and earnings growth despite the generic drug impact. Demographic evolution of the US population should help. I expect RAD to make its entrance in the S&P500 in a not too distant horizon (2 years? which is well inside my investment horizon). It might look a little expensive, and be a little volatile.
I would like to have your thoughts on the company (including on management). Besides reimbursement program, what are the main threats? Is this a good way to get a first direct exposure to the US economy in a portfolio?
Thank you for your help, Eric